HDAC inhibitor

DRUG CLASS:

HDAC inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	belinostat Sensitive: A1 - Approval belinostat Sensitive : A1	belinostat Sensitive: A1 - Approval belinostat Sensitive : A1
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	vorinostat Sensitive: A1 - Approval vorinostat Sensitive : A1	vorinostat Sensitive: A1 - Approval vorinostat Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	panobinostat Sensitive: A2 - Guideline panobinostat Sensitive : A2	panobinostat Sensitive: A2 - Guideline panobinostat Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	romidepsin Sensitive: A2 - Guideline romidepsin Sensitive : A2	romidepsin Sensitive: A2 - Guideline romidepsin Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	CG-781 Sensitive: B - Late Trials CG-781 Sensitive : B	CG-781 Sensitive: B - Late Trials CG-781 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	entinostat Resistant: B - Late Trials entinostat Resistant : B	entinostat Resistant: B - Late Trials entinostat Resistant : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	chidamide Sensitive: B - Late Trials chidamide Sensitive : B	chidamide Sensitive: B - Late Trials chidamide Sensitive : B
GNAQ mutation	Melanoma	GNAQ mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
GNA11 mutation	Melanoma	GNA11 mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
BAP1 mutation	Melanoma	BAP1 mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
HR positive	Breast Cancer	HR positive	Breast Cancer	entinostat Sensitive: C2 – Inclusion Criteria entinostat Sensitive : C2	entinostat Sensitive: C2 – Inclusion Criteria entinostat Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	entinostat Sensitive: C2 – Inclusion Criteria entinostat Sensitive : C2	entinostat Sensitive: C2 – Inclusion Criteria entinostat Sensitive : C2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	HDAC inhibitor + exemestane Sensitive: C2 – Inclusion Criteria HDAC inhibitor + exemestane Sensitive : C2	HDAC inhibitor + exemestane Sensitive: C2 – Inclusion Criteria HDAC inhibitor + exemestane Sensitive : C2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2
HDAC2 expression	Renal Cell Carcinoma	HDAC2 expression	Renal Cell Carcinoma	pazopanib + CG-781 Sensitive: C3 – Early Trials pazopanib + CG-781 Sensitive : C3	pazopanib + CG-781 Sensitive: C3 – Early Trials pazopanib + CG-781 Sensitive : C3
H3.3K27M	Glioma	H3.3K27M	Glioma	panobinostat Sensitive: C3 – Early Trials panobinostat Sensitive : C3	panobinostat Sensitive: C3 – Early Trials panobinostat Sensitive : C3
KMT2D mutation	Diffuse Large B Cell Lymphoma	KMT2D mutation	Diffuse Large B Cell Lymphoma	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3
FLT3-ITD mutation + SKI overexpression	Acute Myelogenous Leukemia	FLT3-ITD mutation + SKI overexpression	Acute Myelogenous Leukemia	HDAC inhibitor Sensitive: C3 – Early Trials HDAC inhibitor Sensitive : C3	HDAC inhibitor Sensitive: C3 – Early Trials HDAC inhibitor Sensitive : C3
S100A9 expression	Multiple Myeloma	S100A9 expression	Multiple Myeloma	bortezomib + panobinostat Resistant: C3 – Early Trials bortezomib + panobinostat Resistant : C3	bortezomib + panobinostat Resistant: C3 – Early Trials bortezomib + panobinostat Resistant : C3
S100A8 expression	Multiple Myeloma	S100A8 expression	Multiple Myeloma	bortezomib + panobinostat Resistant: C3 – Early Trials bortezomib + panobinostat Resistant : C3	bortezomib + panobinostat Resistant: C3 – Early Trials bortezomib + panobinostat Resistant : C3
KMT2A-PTD	Acute Myelogenous Leukemia	KMT2A-PTD	Acute Myelogenous Leukemia	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3
HDAC1 amplification	Soft Tissue Sarcoma	HDAC1 amplification	Soft Tissue Sarcoma	PD1 inhibitor + chidamide Sensitive: C3 – Early Trials PD1 inhibitor + chidamide Sensitive : C3	PD1 inhibitor + chidamide Sensitive: C3 – Early Trials PD1 inhibitor + chidamide Sensitive : C3
TNFRSF8 negative	Peripheral T-cell Lymphoma	TNFRSF8 negative	Peripheral T-cell Lymphoma	chidamide Sensitive: C3 – Early Trials chidamide Sensitive : C3	chidamide Sensitive: C3 – Early Trials chidamide Sensitive : C3
PD-L1 expression	Non-Hodgkin’s Lymphoma	PD-L1 expression	Non-Hodgkin’s Lymphoma	sintilimab + chidamide Sensitive: C3 – Early Trials sintilimab + chidamide Sensitive : C3	sintilimab + chidamide Sensitive: C3 – Early Trials sintilimab + chidamide Sensitive : C3
MYC mutation	Diffuse Large B Cell Lymphoma	MYC mutation	Diffuse Large B Cell Lymphoma	CUDC-907 Sensitive: C3 – Early Trials CUDC-907 Sensitive : C3	CUDC-907 Sensitive: C3 – Early Trials CUDC-907 Sensitive : C3
IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	nivolumab + 4SC-202 Sensitive: C3 – Early Trials nivolumab + 4SC-202 Sensitive : C3	nivolumab + 4SC-202 Sensitive: C3 – Early Trials nivolumab + 4SC-202 Sensitive : C3
LDH-L	Uveal Melanoma	LDH-L	Uveal Melanoma	pembrolizumab + entinostat Sensitive: C3 – Early Trials pembrolizumab + entinostat Sensitive : C3	pembrolizumab + entinostat Sensitive: C3 – Early Trials pembrolizumab + entinostat Sensitive : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	HDAC inhibitor + AKT2 inhibitor Sensitive: C3 – Early Trials HDAC inhibitor + AKT2 inhibitor Sensitive : C3	HDAC inhibitor + AKT2 inhibitor Sensitive: C3 – Early Trials HDAC inhibitor + AKT2 inhibitor Sensitive : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	HDAC inhibitor + AKT1 inhibitor Sensitive: C3 – Early Trials HDAC inhibitor + AKT1 inhibitor Sensitive : C3	HDAC inhibitor + AKT1 inhibitor Sensitive: C3 – Early Trials HDAC inhibitor + AKT1 inhibitor Sensitive : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	romidepsin Sensitive: C3 – Early Trials romidepsin Sensitive : C3	romidepsin Sensitive: C3 – Early Trials romidepsin Sensitive : C3

HDAC inhibitor

HDAC inhibitor

Associations(106)

Associations
(106)